These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 8750621)

  • 1. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
    Martyré MC
    Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC;
    Pathol Biol (Paris); 2001 Mar; 49(2):153-7. PubMed ID: 11317961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC
    Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Megakaryocytes and platelets in myeloproliferative disorders.
    Briere J; Kiladjian JJ; Peynaud-Debayle E
    Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspective in agnogenic myeloid metaplasia.
    Tefferi A; Silverstein MN
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():169-71. PubMed ID: 8951788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet PDGF and TGF-β Levels in Myeloproliferative Disorders.
    Martyré MC
    Leuk Lymphoma; 1991; 6(1):1-6. PubMed ID: 27457569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cells (third of three parts).
    Quesenberry P; Levitt L
    N Engl J Med; 1979 Oct; 301(16):868-72. PubMed ID: 384249
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
    Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
    Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of myeloproliferative disorders.
    Gilbert HS
    Med Clin North Am; 1973 Mar; 57(2):355-93. PubMed ID: 4570933
    [No Abstract]   [Full Text] [Related]  

  • 13. The pathogenesis of spleen mediated phenomena in chronic myeloid leukaemia and agnogenic myeloid metaplasia: a non-abscopal mechanism.
    Adler SS
    Scand J Haematol; 1976 Sep; 17(3):153-9. PubMed ID: 788139
    [No Abstract]   [Full Text] [Related]  

  • 14. Clonal analysis of agnogenic myeloid metaplasia.
    Kreipe H; Jaquet K; Felgner J; Parwaresch MR
    Leuk Lymphoma; 1992 Dec; 8(6):459-64. PubMed ID: 1363649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis.
    Martyré MC; Le Bousse-Kerdiles MC; Romquin N; Chevillard S; Praloran V; Demory JL; Dupriez B
    Br J Haematol; 1997 May; 97(2):441-8. PubMed ID: 9163611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models.
    Chagraoui H; Wendling F; Vainchenker W
    Best Pract Res Clin Haematol; 2006; 19(3):399-412. PubMed ID: 16781480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormal myelopoietic clones in man.
    McCulloch EA
    J Natl Cancer Inst; 1979 Oct; 63(4):883-92. PubMed ID: 384008
    [No Abstract]   [Full Text] [Related]  

  • 19. Stem cell origin of human myeloid blood cell neoplasms.
    Fialkow PJ
    Verh Dtsch Ges Pathol; 1990; 74():43-7. PubMed ID: 1708632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.